ClinConnect ClinConnect Logo
Search / Trial NCT06266767

Programmed Intermittent Epidural Bolus (PIEB) Techniques for Labour Analgesia

Launched by HAMAD MEDICAL CORPORATION · Feb 11, 2024

Trial Information

Current as of May 22, 2025

Completed

Keywords

Obstetrics Analgesia Epidural Patient Controlled Opioid

ClinConnect Summary

Many women experience severe pain during labour. There are many forms of pain relief methods available to women in developed countries. Labour epidural analgesia remains the most effective form of pain relief. It is also the least depressive to the central nervous system of the mother and the baby. After initiating epidural analgesia, there are many regimens that can be employed to maintain analgesia for the duration of labour.

Traditionally, epidural analgesia (using low dose mixtures of local anaesthetic and opioid) has been administered by nurse or midwife-controlled manual boluses or a...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Age 18 to 50 yrs
  • In active labour
  • ASA 2 patients (pregnant patients are considered to be ASA 2)
  • Singleton pregnancy
  • \> 37 weeks gestation
  • Booking BMI 18 to 35
  • Exclusion Criteria:
  • BMI \< 18
  • BMI \> 35
  • Systemic opioids within the previous 6 hours
  • Presence of a fetal anomaly
  • Pre-eclampsia
  • Bleeding disorders (including coagulation disorders)
  • Recent spinal surgery
  • Spinal injury
  • Elevated intracranial pressure (ICP)
  • Neuraxial disorders of any description
  • Signs of local or systemic infection
  • Patient refusal for neuraxial analgesia

About Hamad Medical Corporation

Hamad Medical Corporation (HMC) is a leading healthcare provider in Qatar, dedicated to delivering high-quality medical services and advancing clinical research. As a prominent sponsor of clinical trials, HMC focuses on innovative healthcare solutions that enhance patient outcomes and contribute to the global medical knowledge base. With a robust infrastructure and a commitment to ethical research practices, HMC collaborates with local and international partners to conduct trials across various therapeutic areas, aiming to address pressing health challenges and improve the standard of care within the community. Through its research initiatives, HMC strives to foster a culture of scientific inquiry and evidence-based medicine, ultimately benefiting patients and the healthcare system at large.

Locations

Doha, , Qatar

Patients applied

0 patients applied

Trial Officials

Roshan Fernando, MD

Principal Investigator

Hamad Medical Corporation, Qatar

Fatima Khatoon, DESAIC

Principal Investigator

Hamad Medical Corporation

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported